Kenya is preparing to implement a significant advancement in its public health approach this March through the introduction of Lenacapavir, an injectable medication designed for HIV prevention.
The Ministry of Health has verified the delivery of the first 21,000 starter doses this week, initiating a staged rollout aimed at reducing HIV transmission nationwide.
With administration only required twice annually, Lenacapavir provides six months of protection per dose by inhibiting viral replication and preventing infection establishment.
Health authorities stress that the medication is exclusively for HIV-negative individuals, offering a confidential and highly effective option compared to daily oral Pre-Exposure Prophylaxis (PrEP).
Contemporary international trials have revealed the medication’s exceptional effectiveness, with certain participant groups experiencing a decrease in HIV transmission risk exceeding 99.9%.
The initial implementation phase will concentrate on 15 counties with elevated HIV prevalence, specifically targeting Nairobi, Mombasa, Kisumu, Homa Bay, and Kiambu.
These particular areas were chosen due to substantial HIV infection rates and the capacity of local healthcare centers to handle this new therapeutic option.
The government anticipates a subsequent delivery of 12,000 continuation doses by April, while the United States has pledged an extra 25,000 doses to maintain a consistent availability.